378 related articles for article (PubMed ID: 33638808)
1. Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.
Garon EB; Brodrick P
Drugs; 2021 Apr; 81(5):547-554. PubMed ID: 33638808
[TBL] [Abstract][Full Text] [Related]
2. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Robinson KW; Sandler AB
Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
[TBL] [Abstract][Full Text] [Related]
3. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
4. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Reungwetwattana T; Liang Y; Zhu V; Ou SI
Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
[TBL] [Abstract][Full Text] [Related]
5. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
7. Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
Spagnolo CC; Ciappina G; Giovannetti E; Squeri A; Granata B; Lazzari C; Pretelli G; Pasello G; Santarpia M
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373267
[TBL] [Abstract][Full Text] [Related]
8. Going After
Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
[TBL] [Abstract][Full Text] [Related]
9. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
[TBL] [Abstract][Full Text] [Related]
10. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
[TBL] [Abstract][Full Text] [Related]
11. Progress on treatment of MET signaling pathway in non-small cell lung cancer.
Yu X; Yu S; Fan Y
Int J Clin Oncol; 2020 Aug; 25(8):1450-1458. PubMed ID: 32440811
[TBL] [Abstract][Full Text] [Related]
12. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
[TBL] [Abstract][Full Text] [Related]
13. C-MET inhibitors in the treatment of lung cancer.
Goździk-Spychalska J; Szyszka-Barth K; Spychalski L; Ramlau K; Wójtowicz J; Batura-Gabryel H; Ramlau R
Curr Treat Options Oncol; 2014 Dec; 15(4):670-82. PubMed ID: 25266653
[TBL] [Abstract][Full Text] [Related]
14. Capmatinib in
Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
[TBL] [Abstract][Full Text] [Related]
15. The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Albers J; Friese-Hamim M; Clark A; Schadt O; Walter-Bausch G; Stroh C; Johne A; Karachaliou N; Blaukat A
Mol Cancer Ther; 2023 Jul; 22(7):833-843. PubMed ID: 36999986
[TBL] [Abstract][Full Text] [Related]
16. C-MET inhibitors for advanced non-small cell lung cancer.
Pasquini G; Giaccone G
Expert Opin Investig Drugs; 2018 Apr; 27(4):363-375. PubMed ID: 29621416
[TBL] [Abstract][Full Text] [Related]
17. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.
Landi L; Minuti G; D'Incecco A; Cappuzzo F
Curr Opin Oncol; 2013 Mar; 25(2):130-6. PubMed ID: 23385860
[TBL] [Abstract][Full Text] [Related]
18. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.
Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciardiello F; Gridelli C
Curr Pharm Des; 2012; 18(37):6155-68. PubMed ID: 22873759
[TBL] [Abstract][Full Text] [Related]
19. Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Fujino T; Suda K; Mitsudomi T
Expert Opin Emerg Drugs; 2020 Sep; 25(3):229-249. PubMed ID: 32615820
[TBL] [Abstract][Full Text] [Related]
20. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]